Novavax’s 3,500% Surge on a Covid-19 Vaccine Faces First Test
Vaccine research work at the Torlak Institute of Virology in Belgrade, Serbia. (Photographer: Oliver Bunic/Bloomberg)

Novavax’s 3,500% Surge on a Covid-19 Vaccine Faces First Test

(Bloomberg) -- Novavax Inc.’s Covid-19 vaccine results are expected imminently and scientists will be scanning the data to gauge the shot’s promise. At the same time, day traders -- who’ve snapped ...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.